Titre : Galectine -3

Galectine -3 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Scleroderma, Localized
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Galectine -3 : Questions médicales les plus fréquentes", "headline": "Galectine -3 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Galectine -3 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-17", "dateModified": "2025-02-11", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Galectine -3" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Galectines", "url": "https://questionsmedicales.fr/mesh/D037161", "about": { "@type": "MedicalCondition", "name": "Galectines", "code": { "@type": "MedicalCode", "code": "D037161", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.503.307" } } }, "about": { "@type": "MedicalCondition", "name": "Galectine -3", "alternateName": "Galectin 3", "code": { "@type": "MedicalCode", "code": "D037502", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Çiğdem Yücel", "url": "https://questionsmedicales.fr/author/%C3%87i%C4%9Fdem%20Y%C3%BCcel", "affiliation": { "@type": "Organization", "name": "Department of Biochemistry, University of Health Science, Ankara City Hospital, Ankara, Turkey." } }, { "@type": "Person", "name": "Aybeniz Civan Kahve", "url": "https://questionsmedicales.fr/author/Aybeniz%20Civan%20Kahve", "affiliation": { "@type": "Organization", "name": "Gazi University Faculty of Medicine, Department of Psychiatry, Ankara, Turkey." } }, { "@type": "Person", "name": "Işık Batuhan Çakmak", "url": "https://questionsmedicales.fr/author/I%C5%9F%C4%B1k%20Batuhan%20%C3%87akmak", "affiliation": { "@type": "Organization", "name": "Sungurlu State Hospital, Department of Psychiatry, Corum, Turkey." } }, { "@type": "Person", "name": "Erol Göka", "url": "https://questionsmedicales.fr/author/Erol%20G%C3%B6ka", "affiliation": { "@type": "Organization", "name": "University of Health Sciences, Ankara City Hospital, Department of Psychiatry, Ankara, Turkey." } }, { "@type": "Person", "name": "Massiullah Shafaq-Zadah", "url": "https://questionsmedicales.fr/author/Massiullah%20Shafaq-Zadah", "affiliation": { "@type": "Organization", "name": "Institut Curie, PSL Research University, U1143 INSERM, UMR3666 CNRS, Cellular and Chemical Biology Unit, 75248Paris Cedex 05, France." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Carpal tunnel release under wide awake local anesthesia with no tourniquet in hemodialysis patients with arteriovenous shunt.", "datePublished": "2022-09-17", "url": "https://questionsmedicales.fr/article/36126869", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.otsr.2022.103413" } }, { "@type": "ScholarlyArticle", "name": "A Sparse and Locally Coherent Morphable Face Model for Dense Semantic Correspondence Across Heterogeneous 3D Faces.", "datePublished": "2022-09-14", "url": "https://questionsmedicales.fr/article/34156937", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1109/TPAMI.2021.3090942" } }, { "@type": "ScholarlyArticle", "name": "Alterations in Glomerular Filtration Rates Using Different Algorithms in the Korean Population Visiting Local Clinics and Hospitals.", "datePublished": "2022-09-11", "url": "https://questionsmedicales.fr/article/36142986", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/jcm11185339" } }, { "@type": "ScholarlyArticle", "name": "Vegetation cover and seasonality as indicators for selection of forage resources by local agro-pastoralists in the Brazilian semiarid region.", "datePublished": "2022-09-07", "url": "https://questionsmedicales.fr/article/36071152", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-022-18282-w" } }, { "@type": "ScholarlyArticle", "name": "Sequential therapy of portal vein embolization and systemic chemotherapy for locally advanced perihilar biliary tract cancer.", "datePublished": "2022-09-05", "url": "https://questionsmedicales.fr/article/36089453", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ejso.2022.08.035" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Lectines", "item": "https://questionsmedicales.fr/mesh/D037102" }, { "@type": "ListItem", "position": 5, "name": "Galectines", "item": "https://questionsmedicales.fr/mesh/D037161" }, { "@type": "ListItem", "position": 6, "name": "Galectine -3", "item": "https://questionsmedicales.fr/mesh/D037502" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Galectine -3 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Galectine -3", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-05", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Galectine -3", "description": "Comment mesurer le taux de galectine-3 ?\nQuels tests sont utilisés pour le diagnostic ?\nLa galectine-3 est-elle un biomarqueur ?\nQuels médecins évaluent la galectine-3 ?\nPeut-on détecter la galectine-3 dans l'urine ?", "url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Scleroderma,+Localized&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Galectine -3", "description": "Quels symptômes sont liés à la galectine-3 ?\nLa galectine-3 cause-t-elle des douleurs ?\nY a-t-il des symptômes cardiaques associés ?\nLa galectine-3 est-elle liée à la fatigue ?\nQuels signes cliniques sont observés ?", "url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Scleroderma,+Localized&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Galectine -3", "description": "Comment prévenir l'augmentation de la galectine-3 ?\nL'exercice physique influence-t-il la galectine-3 ?\nY a-t-il des aliments à éviter ?\nLe stress affecte-t-il la galectine-3 ?\nDes suppléments peuvent-ils aider à la prévention ?", "url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Scleroderma,+Localized&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Galectine -3", "description": "Quels traitements ciblent la galectine-3 ?\nLa galectine-3 peut-elle être traitée par des médicaments ?\nY a-t-il des traitements naturels pour la galectine-3 ?\nLes traitements varient-ils selon la maladie ?\nLa thérapie génique peut-elle cibler la galectine-3 ?", "url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Scleroderma,+Localized&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Galectine -3", "description": "Quelles complications sont liées à la galectine-3 ?\nLa galectine-3 aggrave-t-elle les maladies ?\nY a-t-il des risques de cancer associés ?\nLa galectine-3 influence-t-elle la fibrose ?\nDes complications neurologiques sont-elles possibles ?", "url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Scleroderma,+Localized&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Galectine -3", "description": "Quels facteurs augmentent la galectine-3 ?\nLe tabagisme influence-t-il la galectine-3 ?\nL'âge est-il un facteur de risque ?\nLe stress chronique est-il un facteur de risque ?\nY a-t-il un lien avec les maladies auto-immunes ?", "url": "https://questionsmedicales.fr/mesh/D037502?mesh_terms=Scleroderma,+Localized&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment mesurer le taux de galectine-3 ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le taux de galectine-3 se mesure par un test sanguin spécifique." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour le diagnostic ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests sanguins et des examens d'imagerie peuvent être utilisés." } }, { "@type": "Question", "name": "La galectine-3 est-elle un biomarqueur ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle est considérée comme un biomarqueur pour certaines maladies." } }, { "@type": "Question", "name": "Quels médecins évaluent la galectine-3 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les cardiologues et oncologues évaluent souvent la galectine-3." } }, { "@type": "Question", "name": "Peut-on détecter la galectine-3 dans l'urine ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "La galectine-3 est principalement mesurée dans le sang, pas dans l'urine." } }, { "@type": "Question", "name": "Quels symptômes sont liés à la galectine-3 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Elle est associée à des symptômes d'inflammation et de fibrose." } }, { "@type": "Question", "name": "La galectine-3 cause-t-elle des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut contribuer à des douleurs liées à des maladies inflammatoires." } }, { "@type": "Question", "name": "Y a-t-il des symptômes cardiaques associés ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes comme l'essoufflement peuvent être présents." } }, { "@type": "Question", "name": "La galectine-3 est-elle liée à la fatigue ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Elle peut être associée à la fatigue dans des conditions inflammatoires." } }, { "@type": "Question", "name": "Quels signes cliniques sont observés ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme l'œdème et la dyspnée peuvent être observés." } }, { "@type": "Question", "name": "Comment prévenir l'augmentation de la galectine-3 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain, incluant une alimentation équilibrée, peut aider." } }, { "@type": "Question", "name": "L'exercice physique influence-t-il la galectine-3 ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut réduire les niveaux de galectine-3." } }, { "@type": "Question", "name": "Y a-t-il des aliments à éviter ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Éviter les aliments transformés et riches en sucres peut être bénéfique." } }, { "@type": "Question", "name": "Le stress affecte-t-il la galectine-3 ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut augmenter les niveaux de galectine-3." } }, { "@type": "Question", "name": "Des suppléments peuvent-ils aider à la prévention ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Certains suppléments, comme les oméga-3, peuvent être bénéfiques." } }, { "@type": "Question", "name": "Quels traitements ciblent la galectine-3 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des inhibiteurs de galectine-3 sont en développement pour diverses maladies." } }, { "@type": "Question", "name": "La galectine-3 peut-elle être traitée par des médicaments ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments visent à réduire son activité dans le corps." } }, { "@type": "Question", "name": "Y a-t-il des traitements naturels pour la galectine-3 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des approches diététiques et des suppléments peuvent aider à la réguler." } }, { "@type": "Question", "name": "Les traitements varient-ils selon la maladie ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements dépendent de la maladie associée à la galectine-3." } }, { "@type": "Question", "name": "La thérapie génique peut-elle cibler la galectine-3 ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des recherches explorent la thérapie génique pour moduler son expression." } }, { "@type": "Question", "name": "Quelles complications sont liées à la galectine-3 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Elle est liée à des complications cardiovasculaires et pulmonaires." } }, { "@type": "Question", "name": "La galectine-3 aggrave-t-elle les maladies ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle peut aggraver des maladies comme l'insuffisance cardiaque." } }, { "@type": "Question", "name": "Y a-t-il des risques de cancer associés ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux élevés de galectine-3 sont associés à un risque accru de cancer." } }, { "@type": "Question", "name": "La galectine-3 influence-t-elle la fibrose ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle joue un rôle clé dans le développement de la fibrose tissulaire." } }, { "@type": "Question", "name": "Des complications neurologiques sont-elles possibles ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Des études suggèrent un lien entre galectine-3 et maladies neurodégénératives." } }, { "@type": "Question", "name": "Quels facteurs augmentent la galectine-3 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "L'obésité, le diabète et l'inflammation chronique augmentent la galectine-3." } }, { "@type": "Question", "name": "Le tabagisme influence-t-il la galectine-3 ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme est un facteur de risque pour des niveaux élevés." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les niveaux de galectine-3 augmentent souvent avec l'âge." } }, { "@type": "Question", "name": "Le stress chronique est-il un facteur de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le stress chronique peut contribuer à des niveaux élevés de galectine-3." } }, { "@type": "Question", "name": "Y a-t-il un lien avec les maladies auto-immunes ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les maladies auto-immunes peuvent augmenter les niveaux de galectine-3." } } ] } ] }

Sources (10000 au total)

Carpal tunnel release under wide awake local anesthesia with no tourniquet in hemodialysis patients with arteriovenous shunt.

Long-term hemodialysis patients experience many hand diseases caused by dialysis-related amyloidosis (DRA), with carpal tunnel syndrome (CTS) being the most common. For the patients with arteriovenous... This prospective study included 275 hemodialysis patients between March 2013 and July 2019. 43 patients were diagnosed with CTS, involving surgical treatment on 70 wrists. We performed mini-open carpa... The incidence of CTS in hemodialysis patients was 15.6%. Longer dialysis durations were related to higher proportions of patients with CTS. There was no significant difference in blood loss (p=0.184) ... CTS is a very common disease among hemodialysis patients. WALANT provided sufficient hemostasis without a tourniquet, despite the patients' high bleeding tendency. The technique also had the advantage... II....

Sequential therapy of portal vein embolization and systemic chemotherapy for locally advanced perihilar biliary tract cancer.

Curative resection is the only potential treatment for cure in patients with perihilar biliary tract cancer (PBTC). However, post hepatectomy liver failure (PHLF) due to insufficient future liver remn... Between April 2019 and December 2021, 15 patients with locally advanced PBTC (LA-PBTC) underwent sequential treatment consisting of PVE followed by preoperative chemotherapy. The feasibility and effic... Thirteen of 15 patients (86.6%) underwent curative resection. The median duration time between PVE and surgery was 144 days. FRLV/TLV ratio was 31.3% at prePVE, 38.4%, at two weeks after PVE, and 45.7... Sequential PVE and systemic chemotherapy contribute to the sufficient hypertrophy of FRLV without compromising resectability in patients with LA-PBTC....

Locally injected Mesenchymal Stem Cells optimize angiogenesis by regulating VEGF and CD31 expression in duodenal perforation.

Duodenal perforation is considered as one of gastrointestinal emergency with high morbidity and mortality rate. The MSCs have the ability to improve wound healing by releasing several growth factors a... MSCs were isolated from rat umbilical cord and injected into duodenal wound site at doses of 1.5x10 [(Putra et al., 2018) 66 cells for T1 group and 3x10 [(Putra et al., 2018) 66 cells for T2 group. Th... Results showed a significant increase in VEGF and CD31 expression on days 3 and 7 (p < 0,05). The VEGF level was significantly decreased on day 7 compared to day 3.... The administration of MSCs improved the angiogenesis process in duodenal perforation by enhancing VEGF and CD31 expression....

Prediction models for brachytherapy-induced rectal toxicity in patients with locally advanced pelvic cancers: a systematic review.

Rectal toxicity remains a major threat to quality of life of patients, who receive brachytherapy to the abdominal pelvic area. Estimating the risk of toxicity development is essential to maximize ther... To identify relevant studies since 1995, MEDLINE database was searched on August 31, 2021, using terms related to "pelvic cancers", "brachytherapy", "prediction models", and "rectal toxicity". Papers ... Thirty models (... Existing models have limited clinical application due to poor quality of methodology. The following key issues should be considered in future studies: 1) Measuring patient-reported outcomes to address...

Phase I/II trial of local interstitial chemotherapy with arsenic trioxide in patients with newly diagnosed glioma.

Glioma is the most common primary brain tumor in adults with poor prognosis. The glioma patients benefit from STUPP strategy, including maximum and safe resection and adjuvant radiotherapy and chemoth... The arsenic trioxide has the potent therapeutic effect on glioma. However, the safety and efficacy of local interstitial chemotherapy with arsenic trioxide in newly diagnosed glioma patients is unclea... All patients received partial or complete tumor resection and intraoperative implantation of Ommaya reservoirs followed by standard radiotherapy. Arsenic trioxide with the starting dose 0.3 mg was adm... No hematological or grade 4 non-hematological toxicity was observed in any patient during arsenic trioxide treatment. The maximum tolerated dose of 1.5 mg of arsenic trioxide was safe and well tolerat... These results suggest that arsenic trioxide is safe and well tolerated with local delivery into the tumor cavity of the brain, and the dose recommended for a phase II trial is 1.5 mg....

Technical feasibility of robotic vs. laparoscopic surgery for locally advanced colorectal cancer invading the urinary bladder.

The aim of this study was to determine if robotic surgery can reproduce the technical advantages and oncologic outcomes of laparoscopic surgery for the treatment of locally advanced colorectal cancer ... We retrospectively reviewed the prospectively maintained data of patients with locally advanced colorectal cancer invading the urinary bladder undergoing robotic or laparoscopic surgery between June 2... A total of 41 patients (M:F = 32:9; median age: 63 [42-88] years) were analysed; 32 underwent laparoscopic surgery and 9 underwent robotic surgery. There was no statistically significant difference be... Robotic surgery can reproduce the technical advantages and oncologic outcomes of laparoscopic surgery for the treatment of locally advanced colorectal cancer invading the urinary bladder. However, lar...

Entropy reduction from strong localization - an explanation for enhanced reaction rates of organic synthesis in aqueous micelles.

The underlying mechanism for increased reaction rates in micellar catalysis-based organic synthesis is a reduced entropy barrier for the reaction. A two-dimensional localization of reactants and catal... Quantum chemistry, the COSMO-RS implicit solvent model and statistical thermodynamics were employed to predict the stability of a range of reactants, catalysts and intermediates in a series of surfact... The predicted reaction rates for the proposed mechanism show that the entropy reduction leads to a larger prefactor for the reaction. The resulting reaction rate can be significantly higher than conve...